ClinConnect ClinConnect Logo
Search / Trial NCT06993740

Effect of Dexmedetomidine on Microsurgery Reconstruction in Cancer Patient

Launched by DHARMAIS NATIONAL CANCER CENTER HOSPITAL · May 19, 2025

Trial Information

Current as of July 24, 2025

Recruiting

Keywords

Sod 1 Il 6 Il 10 Vegf Syndecan 1 Dexmedetomidine Sdf Pai 1 Flap Failure Flap Salvage

ClinConnect Summary

This clinical trial is studying the effects of a medication called dexmedetomidine on patients with cancer who are undergoing surgery to reconstruct areas of their bodies using tissue flaps. The main goal is to see if administering dexmedetomidine during the surgery can help improve the health and survival of these flaps shortly after the procedure. Researchers will check how well the flaps are doing within 48 hours after surgery by looking at factors like color, temperature, and how quickly blood flows back into the flap. They will also measure certain substances in the body that indicate inflammation, stress, and other important processes that could affect recovery.

To be eligible for this trial, participants should be adults aged 18 to 65 years who have been diagnosed with cancer and are scheduled for this type of reconstructive surgery. However, people with certain health conditions, like uncontrolled diabetes or kidney problems, or those who have received specific treatments before surgery, may not be able to participate. If someone joins the study, they can expect careful monitoring and assessments during their recovery to help understand the effects of the medication on their surgery outcomes.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Adult patients (aged 18-65 years) diagnosed with cancer who are scheduled to undergo microsurgical flap reconstruction.
  • 2. Patients within the age range of 18 to 65 years at the time of enrollment.
  • 3. Patients who provide written informed consent to participate in the study.
  • Exclusion Criteria:
  • 1. Patients with a history of uncontrolled diabetes mellitus.
  • 2. Patients diagnosed with chronic kidney disease.
  • 3. Patients with known liver failure.
  • 4. Patients receiving corticosteroid therapy prior to surgery.
  • 5. Patients with uncontrolled hypertension.
  • 6. Patients with a history of chemotherapy or radiotherapy prior to surgery.
  • 7. Patients diagnosed with preoperative sepsis.
  • 8. Patients requiring perioperative vasopressor support.
  • 9. Patients with a history of prior surgery in the same operative field.
  • 10. Patients who decline to participate in the study.

About Dharmais National Cancer Center Hospital

Dharmais National Cancer Center Hospital is a leading institution dedicated to cancer treatment, research, and education in Indonesia. As a prominent clinical trial sponsor, the hospital focuses on advancing innovative therapies and improving patient outcomes through rigorous scientific investigation. With a multidisciplinary team of experts, Dharmais National Cancer Center Hospital is committed to conducting high-quality clinical trials that adhere to ethical standards and regulatory requirements, fostering collaboration to enhance cancer care both locally and globally.

Locations

Jakarta, Dki Jakarta, Indonesia

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported